Sonoma Pharmaceuticals Enters Manufacturing Agreement
Ticker: SNOA · Form: 8-K · Filed: 2026-04-09T08:30:09-04:00
Sentiment: neutral
Topics: material-agreement, manufacturing, supply-chain
TL;DR
Sonoma Pharma just signed a new manufacturing deal. Big implications for supply chain.
AI Summary
On April 8, 2026, Sonoma Pharmaceuticals, Inc. entered into a material definitive agreement, specifically a Manufacturing and Supply Agreement. The filing details this agreement as a key event, with the full agreement provided as an exhibit.
Why It Matters
This agreement signifies a strategic step for Sonoma Pharmaceuticals in securing its manufacturing capabilities, which could impact product availability and cost.
Risk Assessment
Risk Level: medium — Manufacturing agreements can carry risks related to production quality, supply chain disruptions, and cost fluctuations.
Key Players & Entities
- Sonoma Pharmaceuticals, Inc. (company) — Filer of the 8-K
- 0001367083 (company) — CIK number for Sonoma Pharmaceuticals, Inc.
- 2026-04-09 (date) — Filing Date of the 8-K
- 2026-04-08 (date) — Period of Report for the 8-K
FAQ
What is the nature of the Manufacturing and Supply Agreement?
The filing indicates it is a material definitive agreement, with the full text provided as Exhibit 10.1.
When was this agreement entered into?
The agreement is related to the period of report ending April 8, 2026, and the filing was accepted on April 9, 2026.
What is Sonoma Pharmaceuticals, Inc.'s CIK number?
Sonoma Pharmaceuticals, Inc.'s CIK number is 0001367083.
What are the main items reported in this 8-K filing?
The main items reported are Item 1.01 (Entry into a Material Definitive Agreement) and Item 9.01 (Financial Statements and Exhibits).
Where is Sonoma Pharmaceuticals, Inc. located?
Sonoma Pharmaceuticals, Inc.'s mailing and business address is 5445 CONESTOGA COURT, SUITE 150, BOULDER CO 80301.
From the Filing
EDGAR Filing Documents for 0001683168-26-002761 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001683168-26-002761 Filing Date 2026-04-09 Accepted 2026-04-09 08:30:09 Documents 12 Period of Report 2026-04-08 Items Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits Interactive Data Document Format Files Seq Description Document Type Size 1 CURRENT REPORT sonoma_8k.htm iXBRL 8-K 30705 2 MANUFACTURING AND SUPPLY AGREEMENT sonoma_ex1001.htm EX-10.1 199365 Complete submission text file 0001683168-26-002761.txt 452198 Data Files Seq Description Document Type Size 3 XBRL SCHEMA FILE snoa-20260408.xsd EX-101.SCH 3026 4 XBRL LABEL FILE snoa-20260408_lab.xml EX-101.LAB 34239 5 XBRL PRESENTATION FILE snoa-20260408_pre.xml EX-101.PRE 22366 15 EXTRACTED XBRL INSTANCE DOCUMENT sonoma_8k_htm.xml XML 3195 Mailing Address 5445 CONESTOGA COURT, SUITE 150 BOULDER CO 80301 Business Address 5445 CONESTOGA COURT, SUITE 150 BOULDER CO 80301 800-759-9305 Sonoma Pharmaceuticals, Inc. (Filer) CIK : 0001367083 (see all company filings) EIN. : 680423298 | State of Incorp.: DE | Fiscal Year End: 0331 Type: 8-K | Act: 34 | File No.: 001-33216 | Film No.: 26849912 SIC : 3841 Surgical & Medical Instruments & Apparatus (CF Office: 08 Industrial Applications and Services)